New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...

Obesity is associated with an increased risk of developing breast cancer, and a greater probability for the cancer to spread ...

Life expectancy for people with metastatic or metastasized lung cancer is low. The 5-year survival rate for small cell lung cancer is 3%, and 8% for non-small cell lung cancer (NSCLC). 25-30% of ...

US-based pharmaceutical company Moleculin Biotech has begun dosing subjects in its Phase III MIRACLE trial of Annamycin with ...

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

Radiation oncology, neuro-oncology, and thoracic medical oncology specialists at Memorial Sloan Kettering Cancer Center (MSK) are conducting three clinical trials of new SRS strategies for patients ...

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy and safety profile with IV pembrolizumab.

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

By 2023, approximately 1 in 5 patients with non-small cell lung cancer or metastatic colorectal cancer were treated with a bevacizumab biosimilar.